# Ribociclib (LEE011) Rollover Study for Continued Access

> **NCT02934568** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 22 (actual)

## Conditions studied

- Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies

## Interventions

- **DRUG:** LEE011

## Key facts

- **NCT ID:** NCT02934568
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-12-15
- **Primary completion:** 2027-02-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02934568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02934568, "Ribociclib (LEE011) Rollover Study for Continued Access". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02934568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*